This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.63% per year. These returns cover a period from January 1, 1988 through December 2, 2019. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Company News for Nov 7, 2025
by Zacks Equity Research
Companies In The News Are: CMI, PLNT, PH, AZN.
AZN Q3 Earnings Top Estimates, Sales Rise As Most Key Drugs Outperform
by Zacks Equity Research
AstraZeneca posts strong Q3 results. Core earnings and revenues beat estimates as key drugs like Tagrisso, Imfinzi and Farxiga fuel broad-based growth.
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge.
Pre-Markets Improve on Big Earnings Morning
by Mark Vickery
One might say the relative volatility we started seeing in early October has continued into this month as well.
Compared to Estimates, Astrazeneca (AZN) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amgen's Q3 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
by Zacks Equity Research
AMGN's Q3 earnings and revenues top estimates as key drugs drive double-digit growth. The company also raises its 2025 outlook.
Pfizer Q3 Earnings Beat Estimates, Sales Decline as COVID Demand Cools
by Zacks Equity Research
Pfizer posts Q3 earnings beat and raises EPS guidance, but weaker COVID product sales weigh on overall revenue momentum.
J&J's Innovative Medicines Unit Shows Resilience Amid Stelara LOE
by Kinjel Shah
JNJ's Innovative Medicine unit posts its second straight quarter of more than $15B in sales, driven by Darzalex, Tremfya and Erleada despite Stelara's LOE hit.
Will These 5 Drug Bigwigs Surpass Q3 Earnings Forecasts?
by Kanishka Das
Let's look at five pharma and biotech companies, PFE, AMGN, AZN, VTRS and MRNA, which are scheduled to release their third-quarter 2025 results this week.
Unlocking Q3 Potential of Astrazeneca (AZN): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Astrazeneca (AZN) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Should You Buy, Hold, or Sell BDTX Stock Ahead of Q3 Earnings?
by Ekta Bagri
Black Diamond Therapeutics gears up for Q3 results as investors eye key silevertinib data and additional development plans.
Pfizer Q3 Earnings Loom: Buy, Sell or Hold PFE Stock Ahead of Results?
by Kinjel Shah
Pfizer's Q3 results are due on Nov. 4, with analysts eyeing $16.6B in sales and EPS of 66 cents as investors weigh the stock's next move.
Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook
by Zacks Equity Research
IONS' Q3 results top estimates as robust Tryngolza and Wainua sales drive revenue growth. The company raises its 2025 outlook for the third time this year.
MRK Beats Q3 Earnings Estimates, Narrows 2025 Sales View, Stock Down
by Zacks Equity Research
Merck tops Q3 earnings and revenue estimates on strong oncology, new drugs and animal health sales, while narrowing its 2025 revenue outlook.
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Astrazeneca (AZN) closed at $82.61 in the latest trading session, marking a -1.72% move from the prior day.
Buy, Sell or Hold MRK Stock Ahead of Q3 Earnings? Things to Know
by Kinjel Shah
MRK faces pressure from weak vaccine sales and rising competition, but strong oncology growth and new launches could support a rebound.
Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline
by Zacks Equity Research
Sanofi's Q3 earnings top forecasts as Dupixent surges past EUR 4B in sales, offsetting weakness in vaccines.
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings
by Sundeep Ganoria
LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.
Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?
by Kinjel Shah
Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.
AbbVie Up More Than 30% in 6 Months: How to Play the Stock
by Kinjel Shah
AbbVie's 30% surge in six months is powered by booming sales of Skyrizi and Rinvoq and renewed strength across oncology and neuroscience.
The Zacks Analyst Blog Highlights AstraZeneca, RTX, Applied Materials, Park Aerospace and NetSol Technologies
by Zacks Equity Research
Zacks spotlights AstraZeneca, RTX, and Applied Materials for strong performance and growth potential, while microcap names Park Aerospace and NetSol Technologies show niche momentum.
Top Research Reports for AstraZeneca, RTX & Applied Materials
by Mark Vickery
AstraZeneca, RTX, and Applied Materials stand out in today's Zacks Research Daily with strong performance drivers and key growth catalysts.
Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings
by Sundeep Ganoria
ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Astrazeneca (AZN) closed at $84.69, marking a +1.03% move from the previous day.